Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.

Document Type

Article

Publication Date

7-2019

Identifier

DOI: 10.1002/cpt.1409; PMCID: PMC6612570

Abstract

Atomoxetine is a nonstimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at www.cpicpgx.org).

The purpose of this guideline is to provide information to allow the interpretation of clinical CYP2D6 genotype tests so that the results can be used to guide the use of atomoxetine. Detailed guidelines for prescribing of atomoxetine as well as analyses of cost effectiveness are beyond the scope of this document. The Clinical Pharmacogenetic Implementation Consortium (CPIC) guidelines are periodically updated at https://cpicpgx.org/guidelines and http://www.pharmgkb.org.

Journal Title

Clinical pharmacology and therapeutics

Volume

106

Issue

1

First Page

94

Last Page

102

MeSH Keywords

Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Genetic Testing; Genotype; Humans; Pharmacogenetics

Keywords

Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Genetic Testing; Genotype; Humans; Pharmacogenetics

Link to Full Text
Library Record

Share

COinS